A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib

Leuk Res. 2012 Aug;36(8):e159-62. doi: 10.1016/j.leukres.2012.04.019. Epub 2012 May 11.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amino Acid Substitution / genetics
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Base Sequence
  • Benzamides
  • Codon, Nonsense / genetics
  • Codon, Nonsense / physiology
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics
  • Fusion Proteins, bcr-abl / chemistry
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • Isoleucine / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Models, Molecular
  • Phosphotransferases / chemistry
  • Phosphotransferases / genetics
  • Piperazines / therapeutic use
  • Protein Structure, Tertiary / genetics
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Codon, Nonsense
  • Piperazines
  • Pyrimidines
  • Isoleucine
  • Imatinib Mesylate
  • Phosphotransferases
  • Fusion Proteins, bcr-abl
  • nilotinib